NCT04523181 - Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

December 23, 2021

Study Completion Date

December 23, 2021

Conditions

Covid-19

Interventions

DRUG

Antroquinonol

double-blind for antroquinonol and Placebo with same out-look and same frequency.

OTHER

Placebo

Capsule without active compound

Trial Locations (15)

5000

Sanatorio Privado Mayo SA, Córdoba

Hospital Rawson, Córdoba

15001

Clínica Internacional S.A. - Sede Lima, Lima Cercado

15131

Hospital de Chancay, Chancay

16001

Asociación Civil Selva Amazónica, Iquitos

23000

Hospital III Daniel Alcides Carrion - EsSalud, Tacna

28358

Duke University Southeastern Health, Lumberton

46360

Franciscan Health Michigan City, Michigan City

67214

Ascension.Via Christi Research, Wichita

20850-3357

Adventist Healthcare Shady Grove Medical Center, Rockville

08244

South Jersey Infectious Disease, Somers Point

C1094AAD

Centro Gallego, Buenos Aires

C1426AGU

Clinica de los Virreyes, Buenos Aires

R8500

Clinica Viedma SA, Viedma

07011

Unidad de Investigacion, Hospital Nacional IV Alberto Sabogal Sologuren-Essalud, Red Assitencial Sabogal, Callao